Research Studies

Solid Tumor Program Research Studies

Find research studies available to children cared for by the Solid Tumor Program team.
Existing patients or family members
New patients, referrals and second opinions

Search Research Studies

Clinical trial
Children (17)
Adults (16)
MRI/Imaging Studies (2)

Clinical Trial Phases
Phase I (9)
Phase II (13)
N/A (1)

Recruitment Status
Recruiting (15)
Non-recruiting (2)

Related Specialties and Programs
Cancer Center (17)
Solid Tumor Program (17)
Cancer Immunotherapy Program (1)
Leukemia and Lymphoma Program (1)

Specialty
Oncology (17)

Selpercatinib in Solid or CNS tumors with RET-Alterations
The purpose of this study is to test the safety and efficacy of the investigational drug called Selpercatinib in children whose cancers have a specific genetic change (RET-fusion or RET-mutation). Selpercatinib has been FDA-approved for adults and pediatric patients 12 years of age or older for certain types of lung and thyroid cancers. Selpercatinib is administered in capsule form, liquid suspension, or may also be administered by a feeding tube for subjects who are unable to swallow. 

Phase: Phase I, Phase II

Actively recruiting: Yes

Category: Adults, Children

Selpercatinib in Thyroid Cancer (Collaboration with the International Thyroid Oncology Group)
This study involves taking a study drug called selpercatinib. The overall goal of this study is to find out how effective the study drug is in combination with radioactive iodine (I-131) in treating people with thyroid cancer. The study drug will be given in combination with treatments you will receive as part of your regular cancer care (I-131 and thyrotropin alfa). 

Phase: Phase II

Actively recruiting: Yes

Category: Adults, Children

Selpercatinib RAI Thyroid (RAISE Trial)
This study enrolls patients with newly diagnosed differentiated thyroid cancer (papillary thyroid cancer or follicular thyroid cancer) that has spread to the lungs and has a genetic mutation called and RET fusion. The study involves taking a study drug called selpercatinib for approximately 6 months prior to receiving radioiodine therapy (RAI). The overall goal of this study is to find out if taking the study drug before RAI works better than receiving RAI alone (the usual standard of care treatment). 

Phase: Phase II

Actively recruiting: Yes

Category: Adults, Children, MRI/Imaging Studies

Synovial Sarcoma Registry/Biospecimen Repository

The Synovial Sarcoma Registry and Biospecimen Repository was opened in June of 2023 with the goal of furthering research and improving outcomes for patients with synovial sarcoma. This study is open to anyone treated in the United States. You do NOT have to travel to Philadelphia to participate.

Actively recruiting: Yes

Category: Adults, Children

TAPISTRY

The purpose of this study is to evaluate the effects, good or bad, of targeted therapies or immunotherapy (drugs that help the body's immune system fight cancer cells) in patients who have solid tumors with specific genetic alterations or with a high number of mutations. Patients will be assigned to cohorts (groups) based on having a specific type of genetic alteration in their tumor. The study includes cohorts for patients whose tumors have genetic alterations in the ROS1, NTRK, PIK3CA, BRAF, or RET genes or a high number of mutations in their tumor.

Phase: Phase II

Actively recruiting: No

Category: Adults, Children

Tegavivint for the Treatment of Solid Tumors, Lymphomas & Desmoids
This study has two parts. Part A enrolls patients who have been diagnosed with a solid tumor, lymphoma or desmoid tumor that has either come back ("relapsed") or does not respond to therapy ("is refractory"). Part B enrolls patients with a relapsed or refractory Ewing sarcoma, desmoid tumor, osteosarcoma, liver tumor, Wilms tumor, or tumors with changes in a gene family known as the Wnt pathway. This study involves taking a study drug called tegavivint. The study will be testing different doses of the study drug to find the safest dose. 

Phase: Phase I, Phase II

Actively recruiting: Yes

Category: Adults, Children

Tiragolumab and Atezolizumab in SMARCB1 or SMARCA4 Deficient Tumors
This study enrolls patients that have been diagnosed with SMARCB1 or SMARCB4 deficient cancer that has either come back (“relapsed”) or does not respond to therapy (“is refractory”) or have been newly diagnosed with a SMARCB1 or SMARCB4 deficient cancer that has no known standard treatment. This study involves taking study drugs called tiragolumab and atezolizumab. These drugs are a type of immunotherapy that try to make the immune system fight cancer. The purpose of the study is to learn more about the safety of tiragolumab in children and to see how well the combination of tiragolumab and atezolizumab works when given to children and adults with these types of tumors. This study has two parts. In Part A, participants will receive tiragolumab. In Part B, participants will receive both tiragolumab and atezolizumab. 

Phase: Phase I, Phase II

Actively recruiting: Yes

Category: Adults, Children